CD274 and head and neck squamous cell carcinoma: In recurrent and/or metastatic head and neck squamous cell cancer (HNSCC) PD-1 inhibitors have response rates of around 13% in unselected patients [3] and also only 19% after PD-L1 based patient selection (CPS score ≥ 1) [4].